A New FDA-Approved Technology Aids Surgeons in Real-Time Lung Cancer Lesion Detection

The U.S. Food and Drug Administration (FDA) approved the LungVision system in July 2023, a technology developed by Spectral MD that enables surgeons to identify lung cancer lesions during surgery using near-infrared spectroscopy, according to the FDA. The device, which analyzes tissue characteristics in real time, aims to enhance precision during lung cancer removal procedures, potentially reducing the need for follow-up surgeries.

How the Technology Works

LungVision employs near-infrared light to measure metabolic activity in lung tissue, distinguishing cancerous from non-cancerous areas during surgery. Surgeons use a handheld probe to scan tissue, with results displayed on a monitor within seconds. The system’s algorithm, validated through clinical trials, identifies molecular signatures associated with malignancy, according to a 2023 study published in *The Journal of Thoracic and Cardiovascular Surgery*.

Expert Perspectives on Clinical Impact

Dr. Sarah Lin, a thoracic surgeon at Johns Hopkins Hospital, noted that the technology addresses a critical challenge in lung cancer surgery: accurately delineating tumor margins. “Traditional methods rely on visual inspection and frozen section pathology, which can be time-consuming and less precise,” she said. “LungVision provides immediate feedback, potentially improving outcomes.”

The FDA’s approval was based on data from a multicenter trial involving 150 patients, which demonstrated a 92% accuracy rate in identifying malignant tissue, according to the agency’s public docket. However, the agency emphasized that further research is needed to evaluate long-term benefits.

Comparative Advantages Over Traditional Methods

Compared to conventional techniques, LungVision offers faster intraoperative decision-making. Traditional frozen section pathology, for example, can take 20–30 minutes per sample, while the new system provides results in under 10 seconds. A 2022 review in *Cancer Surgery* highlighted that delayed decision-making during surgery increases the risk of incomplete tumor removal, a challenge the technology aims to mitigate.

What’s Next for the Technology?

Spectral MD plans to seek additional approvals for the device in other cancer types, including breast and colorectal cancers, according to a company press release. Meanwhile, the National Cancer Institute (NCI) is funding a larger trial to assess whether LungVision reduces reoperation rates, with results expected by 2025.

As adoption grows, the technology could reshape surgical protocols for lung cancer, aligning with broader trends in precision medicine. However, experts caution that integration into routine practice will require training and validation across diverse patient populations.